Europe-wide Expansion to support delivery of mRNA Therapies

Biotechnology business Moderna has announced plans to extend its global footprint by establishing a commercial presence in Belgium, Denmark, Norway, the Netherlands, Poland and Sweden, supporting the delivery of mRNA vaccines and therapeutics locally. This follows the recent announcement of plans for four new subsidiaries in Malaysia, Taiwan, Singapore and Hong Kong.

“Europe has played a critical role in Moderna’s ability to manufacture and deliver our COVID-19 vaccine across the world, protecting millions of people from COVID-19 infection, hospitalization, and death. After a decade of pioneering the development of our mRNA platform, I am proud of the growth we continue to achieve,” said Stéphane Bancel, Chief Executive Officer of Moderna. “I look forward to furthering our collaborations with European researchers and partners to leverage our mRNA technology and expand treatment options to improve the lives of patients across Europe.”

Existing commercial subsidiaries in Italy, France, Germany, Spain, Switzerland and the United Kingdom were joined by Moderna Poland last year, which hosts the company’s International Business Services (MIBS) Centre, providing critical functions such as finance, pharmacovigilance, human resources and digital services. There are also plans to expand its commercial capabilities. Moderna also has several key manufacturing partnerships across Europe, including Lonza in Switzerland and the Netherlands, ROVI in Spain, and Recipharm in France. 

As well as continuing to update its COVID-19 strategy to address variants of concern, the company is developing mRNA medicines to potentially prevent and treat diseases with significant unmet needs across infectious diseases, immuno-oncology, rare and ultra-rare diseases, and autoimmune diseases with 25 of 40 development programmes currently in clinical trials.

Regulators have approved Moderna’s COVID-19 vaccine in more than 70 countries, including Canada, Japan, the European Union, the UK, and Israel. In 2021, 807 million doses of Moderna's COVID-19 vaccine were shipped globally, with approximately 25% of those doses shipped to low- and middle-income countries.

In the European Union, the Company’s COVID-19 vaccine and booster are approved for use by the European Commission for active immunisation to prevent COVID-19 caused by the SARS-CoV-2 virus in individuals 18 years of age and older. To date, the European Commission has ordered 460 million doses of Moderna’s COVID-19 vaccine, including boosters and the ability to purchase other COVID-19 vaccine candidates from Moderna’s pipeline.

More information online